Breast cancer (BC) is the most common cancer in the world as well as the most common malignancy in Korean women, and the incidence continues to increase [1, 2]. Due to increased early detection with cancer screening programs and advances in systemic treatment such as chemotherapy, anti-hormone therapy, and human epidermal growth factor 2 (HER2)-targeted therapy, more patients are surviving after treatment for BC [3].

Current surveillance guidelines for follow-up after a diagnosis of BC recommend regular mammography (MMG) and physical examinations as well as further symptom-related laboratory tests and imaging tests, such as computed tomography (CT) or positron emission tomography-CT scans [4, 5]. These guidelines are based on data from clinical trials performed in the early 1990’s, which did not show any survival benefit with the early detection of distant metastasis [6, 7]. However, those clinical trials were mainly conducted using imaging modalities with poor sensitivity (e.g., chest X-ray), physical examinations with examiner-dependent variation of sensitivity (e.g., abdominal sonography), or procedures with limited specificity (e.g., bone scan), and did not include tumor markers (e.g., cancer antigen 15–3 [CA15-3]).

CA15-3 is a serum tumor marker for BC extensively used in clinical practice. CA15-3 is non-invasive, easily available, and a cost-effective tumor marker for immediate diagnosis, monitoring, and prediction of BC in early, advanced, and metastatic BC [8, 9, 10]. However, to the best of our knowledge, its clinical value within normal range has not been assessed. We hypothesized that an elevation of CA15-3 levels which were initially within normal ranges in patients with early BC could affect recurrence of BC; thus, the association between elevated CA15-3 levels and BC recurrence was analyzed in the present study.

She said that the new framework represents a “landmark step,” and that the measure could allow conservationists to consider new ways to address the risks of climate change or test new methods of suppressing disease.

The IUCN — a large group of conservation organizations, governments and Indigenous groups with more than 1,400 members from about 160 countries — meets once every four years. It is the world’s largest network of environmental groups and the authority behind the red list, which tracks threatened species and global biodiversity.

Made by U.S. pharmaceutical company Grail, the Galleri test aims to find fragments of DNA in a person’s blood that can indicate the presence of a cancerous tumor. Among the cancers that the test can detect, many have no current screening programs.

The PATHFINDER 2 study included more than 36,000 people aged 50 and older who had no cancer symptoms. In participants who were followed for more than a year, the test caught some 40.4% of cancer cases. For those who got a positive result on the Galleri test, 61.6% of them went on to be diagnosed with cancer—an improvement over previous trials of the test.

The results were presented on Saturday at the European Society for Medical Oncology meeting in Berlin, and have yet to be published in a peer-reviewed journal.